HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.

MLA

Suzuki, Fumitaka, et al. “HBe Antigen Loss during Lamivudine Therapy Is Not Caused by Mutations in Precore and Core Promoter Genes in Patients with Chronic Hepatitis B.” Journal of Medical Virology, vol. 70, no. 3, July 2003, pp. 355–60. EBSCOhost, https://doi.org/10.1002/jmv.10403.

APA

Suzuki, F., Tsubota, A., Arase, Y., Suzuki, Y., Akuta, N., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Ikeda, K., Kobayashi, M., Matsuda, M., Satoh, J., Takagi, K., & Kumada, H. (2003). HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B. Journal of Medical Virology, 70(3), 355–360. https://doi.org/10.1002/jmv.10403

Chicago

Suzuki, Fumitaka, Akihito Tsubota, Yasuji Arase, Yoshiyuki Suzuki, Norio Akuta, Tetsuya Hosaka, Takashi Someya, et al. 2003. “HBe Antigen Loss during Lamivudine Therapy Is Not Caused by Mutations in Precore and Core Promoter Genes in Patients with Chronic Hepatitis B.” Journal of Medical Virology 70 (3): 355–60. doi:10.1002/jmv.10403.